CTx001 an AAV2 Mini-CR1 Gene Therapy for dry AMD in Phase-I/II clinical trials: in-vitro and in-vivo Studies Show Potent Complement Target Engagement and Inhibition on different cellular and animal models (ESGCT 2026) - Sep 11, 2026 - Abstract #P0749; No abstract available
Gene therapy • P1/2 data • Preclinical • Dry Age-related Macular Degeneration • Gene Therapies • CR1
|